Depot fluphenazine: risk/benefit ratio.
The risks and benefits associated with depot fluphenazine are reassessed by a review and critique of the literature, with an emphasis on controlled studies comparing depot to oral preparations. Specific gaps in our knowledge are noted and recommendations are made for future research.
D000284:Administration, Oral; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D002986:Clinical Trials as Topic; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D005260:Female; D005476:Fluphenazine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D010349:Patient Compliance; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000523:psychology; D011954:Receptors, Dopamine / Q000187:drug effects; D012107:Research Design / Q000592:standards; D012306:Risk; D012559:Schizophrenia / Q000188:drug therapy / Q000517:prevention & control; D012565:Schizophrenic Psychology
D011954:Receptors, Dopamine; C011825:fluphenazine depot; C017610:fluphenazine enanthate; D005476:Fluphenazine